Prostate cancer (PCa) affects males of all racial and ethnic groups, and leads to higher rates of mortality in those belonging to a lower socioeconomic status due to the late detection of the disease. PCa affects middle-aged males between the ages of 45 and 60 years, and is the highest cause of cancer-associated mortality in Western countries. As the most abundant and common mRNA modification in higher eukaryotes, N 6-methyladenosine (m 6A) is widely distributed in mammalian cells and influences various aspects of mRNA metabolism. Recent studies have found that abnormal expression levels of various m 6A regulators significantly affect the development and progression of various types of cancer, including PCa. The present review discusses the influence of m 6A regulatory factors on the pathogenesis and progression of PCa through mRNA modification based on the current state of research on m 6A methylation modification in PCa. It is considered that the treatment of PCa with micro-molecular drugs that target the epigenetics of the m 6A regulator to correct abnormal m 6A modifications is a direction for future research into current diagnostic and therapeutic approaches for PCa.